Eloxx Stock Moves Higher On Fast Track Tag For Cystic Fibrosis Candidate
- The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc's (NASDAQ: ELOX) ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations.
- ELX-02 is currently in Phase 2 clinical trials. It expects to present data from the first four treatment arms in the fourth quarter of 2021.
- Related Content: Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021.
- ELX-02 has previously been granted orphan drug designation by the FDA and orphan medicinal product designation by the European Medicines Agency.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: ELOX stock is up 12.60% at $1.57 during the market session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech Long Ideas News Penny Stocks Health Care FDA Movers Trading Ideas
